The effect of sub-inhibitory concentrations of rifaximin on urease production and on other virulence factors expressed by Klebsiella pneumoniae, Proteus mirabilis, Pseudomonas aeruginosa and Staphylococcus aureus

Unraveling the Physiological Complexities of Antibiotic Lethality

(2015) Daniel J. Dwyer et al.   Annual Review of Pharmacology and Toxicology

Synergistic, collaterally sensitive β-lactam combinations suppress resistance in MRSA

(2015) Patrick R Gonzales et al.   Nature Chemical Biology

Rifaximin: beyond the traditional antibiotic activity

(2014) Fiorella Calanni et al.   JOURNAL OF ANTIBIOTICS

Effects of Rifaximin on Bacterial Virulence Mechanisms at Supra- and Sub-Inhibitory Concentrations

(2014) E.A. Debbia et al.   JOURNAL OF CHEMOTHERAPY

The Emerging Role of Urease as a General Microbial Virulence Factor

(2014) Julian C. Rutherford   PLoS Pathogens

The Effect of Rifaximin on Gut Flora and Staphylococcus Resistance

(2013) Mi-Sung Kim et al.   DIGESTIVE DISEASES AND SCIENCES

Pseudomonas aeruginosa: new insights into pathogenesis and host defenses

(2013) Shaan L. Gellatly et al.   Pathogens and Disease

Rifaximin: New Therapeutic Indication and Future Directions

(2011) Anastasia Rivkin et al.   CLINICAL THERAPEUTICS

109 LONG TERM EFFICACY AND SURVIVAL IN PATIENTS TREATED WITH THE GUT-SELECTIVE ANTIBIOTIC RIFAXIMIN (550 MG BID) FOR THE MAINTENANCE OF REMISSION FROM OVERT HEPATIC ENCEPHALOPATHY

(2011) K.D. Mullen et al.   JOURNAL OF HEPATOLOGY

Rifaximin in the treatment of inflammatory bowel disease

(2011) Mario Guslandi   WORLD JOURNAL OF GASTROENTEROLOGY

Rifaximin Treatment in Hepatic Encephalopathy

(2010) Nathan M. Bass et al.   NEW ENGLAND JOURNAL OF MEDICINE

Review of rifaximin as treatment for SIBO and IBS

(2009) Mark Pimentel   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Rifaximin for maintenance therapy in antibiotic-dependent pouchitis

(2008) Bo Shen et al.   BMC GASTROENTEROLOGY